@ARTICLE{
author={Dimopoulos Meletios Athanasios,Terpos Evangelos,Boccadoro Mario,Delimpasi Sosana,Beksac Meral,Katodritou Eirini,Moreau Philippe,Baldini Luca,Symeonidis Argiris,Bila Jelena S,Oriol Albert,Mateos Maria-Victoria,Einsele Hermann,Orfanidis Ioannis,Kampfenkel Tobias,Liu Weiping,Kosh Michele,NamPhuong Tran,Carson Robin,Sonneveld Pieter},
year={2022},
title={Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study},
journal={BLOOD},
volume={140},
number={},
pages={7272-7274},
document_type={Meeting Abstract},
}